kffhealthnews.org ·
pharmacy discount coupons hidden costs
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe decline in manufacturer coupon usage for obesity drugs reduces patient out-of-pocket savings but may lower drugmaker revenue if demand softens. Insurance policies (copay accumulators) shift cost to patients, potentially reducing adherence and volume. No direct supply chain or commodity impact; mechanism is regulatory/insurance-driven affecting drug affordability and manufacturer pricing power. Weak commercial mechanism; no specific company or product price mentioned.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Manufacturer-sponsored drug coupon use for obesity drugs fell from 54.6% in 2017 to 2.5% in 2024.
- Study published April 6 in JAMA.
- Copay accumulators and maximizers exclude coupon values from deductibles.
- Uninsured patients may benefit from coupons.
- Medicare/Medicaid patients prohibited from using coupons due to anti-kickback laws.